New hope for Tough-to-Treat blood cancers: phase 3 trial launches
NCT ID NCT07139873
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called DZD8586 against standard treatments in 250 adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has come back or stopped responding to prior therapy. The main goal is to see if DZD8586 can delay cancer growth longer than the doctor's choice of current treatments. Participants are randomly assigned to receive either DZD8586 or another approved therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, China
-
National Clinical Research Center for Blood Diseases, Blood Disease Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITINGTianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New BTK blocker aims to outsmart drug resistance in elderly CLL patients
- New combo aims to shorten CLL treatment
- New pill shows promise against Hard-to-Treat blood cancers
- New cocktail aims to tame Slow-Growing blood cancers
- Could a cancer drug tame a blood disorder?
- Triple threat: new drug cocktail aims to wipe out CLL/SLL